Akeso
Clinical trials sponsored by Akeso, explained in plain language.
-
New drug duo shows promise for tough cancers
Disease control CompletedThis study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New Antibody-Chemo cocktail shows promise for tough lung cancers
Disease control CompletedThis phase II trial tested a new drug called AK104 (a bispecific antibody that targets two immune checkpoints) combined with the chemotherapy docetaxel in 44 adults with advanced non-small cell lung cancer whose disease had progressed after platinum-based chemotherapy and an anti…
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New shot could ease back pain for ankylosing spondylitis patients
Disease control CompletedThis study tested a drug called AK111 in 510 adults with active ankylosing spondylitis, a type of arthritis that causes back pain and stiffness. Participants received either AK111 or a placebo as a shot under the skin over 48 weeks. The main goal was to see if AK111 improves symp…
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control CompletedThis study tested a new drug, AK120, in 450 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check for side effects and see how well the drug works. Researchers measured changes in eczema severity using standard skin scores.
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New bispecific antibody shows promise for unresectable liver cancer
Disease control CompletedThis phase II trial tested a drug called AK112 in 40 people with advanced liver cancer that could not be removed by surgery. AK112 is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth. The study measured safety and how well the drug shrank …
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New Dual-Action drug shows promise in advanced lung cancer trial
Disease control CompletedThis trial tested a new drug called AK112 in 108 people with advanced non-small cell lung cancer. The drug targets both PD-1 and VEGF to attack cancer cells and cut off their blood supply. The study aimed to see if the drug shrinks tumors and how safe it is. Participants had stag…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Immunotherapy combo shows promise in stomach cancer trial
Disease control CompletedThis phase 3 trial tested whether adding an immunotherapy drug called AK104 to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. About 610 participants received either AK104 plus chemo or a placebo plus chemo. The study is c…
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Healthy men test new drug to see if different factories make it the same
Knowledge-focused CompletedThis early-stage study tested a single injection of ebronucimab in 230 healthy Chinese men to see if different production methods change how the drug behaves in the body. The main goal was to measure drug levels in the blood and check for side effects. This trial does not aim to …
Phase: PHASE1 • Sponsor: Akeso • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC